Cell Line News and Research

RSS

Tumor-suppressing protein acts as dimmer switch to dial down gene expression

A tumor-suppressing protein acts as a dimmer switch to dial down gene expression. It does this by reading a chemical message attached to another protein that's tightly intertwined with DNA, a team led by scientists at The University of Texas MD Anderson Cancer Center reported at the AACR Annual Meeting 2014.

11 Apr 2014

Acupuncture protects brain neurons against injury in rats following heroin relapse

Heroin abuse can damage many brain areas, including the pedunculopontine tegmental nucleus of the midbrain, the ventral tegmental area, and nucleus accumbens. Persistent use of heroin induced irreversible damage to the nervous system.

11 Apr 2014

Production of Immutep’s ImmuFact IMP321 starts at WuXi AppTec facilities in China

Immutep S.A., the biopharmaceutical company specializing in immuno-oncology, and Eddingpharm have started production of Immutep’s ImmuFact IMP321 (a LAG-3Ig fusion protein) at WuXi AppTec facilities in China. The product is being produced to European, U.S. and Chinese GMP standards.

8 Apr 2014

Combination therapy with MEK and BRAF inhibitors for anaplastic thyroid cancer proves effective

Researchers from the Jacks Laboratory at MIT's Koch Institute for Integrative Cancer Research (KI) have developed and characterized a genetically engineered mouse that successfully models progression from papillary thyroid cancer, which has an excellent prognosis, to anaplastic thyroid cancer (ATC), a highly lethal disease.

8 Apr 2014

Inhibiting cancer-promoting prolactin causes unconventional cell death in preclinical research

Under stress from chemotherapy or radiation, some cancer cells dodge death by consuming a bit of themselves, allowing them to essentially sleep through treatment and later awaken as tougher, resistant disease.

4 Apr 2014

High levels of GDNF protein could help body resist weight gain despite high-fat diet

More than one-third of people in the US are obese. Obesity and its related health problems-including high blood pressure, high cholesterol, diabetes, insulin resistance, and belly fat-affect so many, yet effective treatments are very few.

2 Apr 2014

Patrys provides update on development programme for anti-cancer product, PAT-LM1

Patrys Limited, a clinical stage biotechnology company, is pleased to provide an update on the development programme for anti-cancer product, PAT-LM1.

24 Mar 2014

Researchers create new line of human embryonic stem cells

Researchers at the University of Washington have successfully created a line of human embryonic stem cells that have the ability to develop into a far broader range of tissues than most existing cell lines.

18 Mar 2014

ChromaTrap™ Chromatin Immunoprecipitation technology receives positive commentary in published paper

Porvair Sciences reports on positive commentary by researchers in published papers citing how using the fast, sensitive ChromaTrap™ Chromatin Immunoprecipitation (ChIP) technology has benefited their research.

From Chromatrap® - Porvair Sciences Ltd 18 Mar 2014

Plymouth University doctor wins national award for animal testing alternative

Dr. Gyorgy Fejer from Plymouth University School of Biomedical and Healthcare Sciences has received a national award for his work developing the lab-based creation of a type of mouse cell line which could be used in place of live animals for research related to infectious diseases.

4 Mar 2014

Researchers create new probe that freezes cells to "see" at greater detail without damaging

It's an odd twist. For scientists to determine if a cell is functioning properly, they must destroy it. This is what happens in X-ray fluorescence microscopy when biological specimens are exposed to ionizing radiation, which provides images with a level of detail that conventional microscopes just can't match.

26 Feb 2014

DFTD study explains how human selection alters evolution of cancerous cells

Tasmanian Devil Facial Tumour Disease (DFTD) has ravaged the world's largest carnivorous marsupial since it emerged in 1996, resulting in a population decline of over 90%.

19 Feb 2014

IGF1R linked to mutation-negative lung cancer erlotinib resistance

Activation of the insulin-like growth factor 1 receptor plays a key role in acquired resistance to erlotinib in lung cancer with wild-type epidermal growth factor receptor, research suggests.

18 Feb 2014

Horizon Discovery, Haplogen sign worldwide distribution agreement

Horizon Discovery, a leading provider of research tools to support translational genomics and the development of personalized medicines, today announced it has signed a worldwide distribution agreement with Haplogen GmbH, with immediate effect.

12 Feb 2014

Splicing findings offer lung cancer clues

Researchers from Spain have identified several new splicing events regulated by the oncogenic splicing factor SRSF1 in lung cancer, suggesting that their dysregulation is involved in the pathogenesis of the disease.

4 Feb 2014

Drug used to treat schizophrenia, dementia has potential for treating liver disease

Opening up a can of worms is a good way to start hunting for new drugs, recommend researchers from Children's Hospital of Pittsburgh of UPMC and the University of Pittsburgh School of Medicine.

4 Feb 2014

Dormant prostate cancer cells within bone tissue can be reawakened to a cancerous state

Dormant prostate cancer cells in bone tissue can be reawakened to cause secondary tumours, according to new research published in Endocrine-Related Cancer. Targeting the wake-up call could prevent metastasis and improve prostate cancer survival rates.

29 Jan 2014

Rival proteins’ relative expression levels in cancer cells could be biomarkers for prognosis, treatment

Consider two drivers, each with a key that fits the same car. Driver 1 wants simply to turn on the ignition and leave the vehicle idling, ready and waiting to roll. Driver 2 wants to take it on a destructive joy ride.

24 Jan 2014

Axxam, Cellectis bioresearch partner to offer cell-based assays to Life Science industry

Axxam (Milan), a leading provider of discovery services including assay development for high-throughput screening, and Cellectis bioresearch (Paris), the cell engineering expert, have started a collaboration to offer to the Life Science industry an extensive range of integrated discovery services based on genomic engineering technologies.

19 Jan 2014

Transgenomic, Horizon Discovery collaborate to develop improved genetic diagnostic tests with state of art controls

Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, and Horizon Discovery Ltd. (Horizon), a leading provider of research tools to support translational genomics and the development of personalized medicines, today announced they have entered into a collaboration agreement to develop improved genetic diagnostic tests incorporating state of the art controls.

16 Jan 2014